Literature DB >> 24238689

Current management of lupus nephritis.

Frédéric A Houssiau1, Bernard R Lauwerys.   

Abstract

Despite decades of clinical research aimed at finding the most appropriate immunosuppressive regime, lupus nephritis (LN) remains one of the major disease manifestations of systemic lupus erythematosus (SLE) with a great impact on survival and quality of life. We start this review by defining the disease burden, the real-world challenges and the poor prognostic factors. We then discuss the current anti-inflammatory, cytotoxic and biologic therapies, with special emphasis on the need for optimal global care.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Immunosuppression; Lupus nephritis; Optimal care; Treatment

Mesh:

Substances:

Year:  2013        PMID: 24238689     DOI: 10.1016/j.berh.2013.07.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  17 in total

Review 1.  Lupus nephritis: an update.

Authors:  Tasnim F Imran; Frederick Yick; Suneet Verma; Christopher Estiverne; Chinonye Ogbonnaya-Odor; Srikanth Thiruvarudsothy; Alluru S Reddi; Neil Kothari
Journal:  Clin Exp Nephrol       Date:  2015-10-16       Impact factor: 2.801

2.  Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort.

Authors:  Jayne Little; Ben Parker; Mark Lunt; John G Hanly; Murray B Urowitz; Ann E Clarke; Juanita Romero-Diaz; Caroline Gordon; Sang-Cheol Bae; Sasha Bernatsky; Daniel J Wallace; Joan T Merrill; Jill Buyon; David A Isenberg; Anisur Rahman; Ellen M Ginzler; Michelle Petri; Mary Anne Dooley; Paul Fortin; Dafna D Gladman; Kristjan Steinsson; Rosalind Ramsey-Goldman; Munther A Khamashta; Cynthia Aranow; Meggan Mackay; Graciela S Alarcón; Susan Manzi; Ola Nived; Andreas Jönsen; Asad A Zoma; Ronald F van Vollenhoven; Manuel Ramos-Casals; Guillermo Ruiz-Irastorza; Sung Sam Lim; Kenneth C Kalunian; Murat Inanc; Diane L Kamen; Christine A Peschken; Soren Jacobsen; Anca Askanase; Jorge Sanchez-Guerrero; Ian N Bruce
Journal:  Rheumatology (Oxford)       Date:  2018-04-01       Impact factor: 7.580

3.  The expression of EBV-encoded LMP1 in young patients with lupus nephritis.

Authors:  Yan Ding; Xiaojie He; Wang Liao; Zhuwen Yi; Huilan Yang; Wei Xiang
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 4.  A systems approach to renal inflammation in SLE.

Authors:  Celine C Berthier; Matthias Kretzler; Anne Davidson
Journal:  Clin Immunol       Date:  2016-08-14       Impact factor: 3.969

Review 5.  The contribution of the programmed cell death machinery in innate immune cells to lupus nephritis.

Authors:  FuNien Tsai; Harris Perlman; Carla M Cuda
Journal:  Clin Immunol       Date:  2016-10-22       Impact factor: 3.969

6.  AGS, SLE, and RNASEH2 mutations: translating insights into therapeutic advances.

Authors:  William F Pendergraft; Terry K Means
Journal:  J Clin Invest       Date:  2014-12-15       Impact factor: 14.808

Review 7.  Reviewing the recommendations for lupus in children.

Authors:  Zehra Serap Arıcı; Ezgi Deniz Batu; Seza Ozen
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

Review 8.  What is damaging the kidney in lupus nephritis?

Authors:  Anne Davidson
Journal:  Nat Rev Rheumatol       Date:  2015-11-19       Impact factor: 20.543

Review 9.  Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials.

Authors:  Kristin M Corapi; Mary Anne Dooley; William F Pendergraft
Journal:  Arthritis Res Ther       Date:  2015-04-28       Impact factor: 5.156

10.  A Systematic Review and Meta-analysis of Prevalence of Biopsy-Proven Lupus Nephritis.

Authors:  Hong Wang; Yi-le Ren; Jun Chang; Luo Gu; Ling-Yun Sun
Journal:  Arch Rheumatol       Date:  2017-07-25       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.